CSIMarket Company Name, Ticker, Suppliers, else..
 
Bio path Holdings Inc  (BPTH)
Other Ticker:  
 
 
Price: $1.1900 $0.34 39.786%
Day's High: $1.44 Week Perf: 34.87 %
Day's Low: $ 0.96 30 Day Perf: 20.21 %
Volume (M): 65,672 52 Wk High: $ 21.60
Volume (M$): $ 78,150 52 Wk Avg: $5.37
Open: $1.28 52 Wk Low: $0.85



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 2
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0

Bio Path Holdings Inc
Bio-Path Holdings Inc. is a clinical-stage biotechnology company that focuses on developing therapeutic products to treat cancer and other diseases. It is headquartered in Houston, Texas. The company's proprietary technology platform, known as DNAbilize, uses synthetic oligonucleotides to deliver cancer-fighting drugs directly to cancer cells. This targeted approach is designed to enhance the effectiveness of the drugs while minimizing side effects. Bio-Path Holdings has a pipeline of drug candidates in various stages of development, targeting different types of cancer, including acute myeloid leukemia and solid tumors. The company is committed to advancing innovative treatments for patients with unmet medical needs in the oncology field.


   Company Address: 4710 Bellaire Boulevard, Suite 210 Bellaire 77401 TX
   Company Phone Number: 742-1357   Stock Exchange / Ticker: NASDAQ BPTH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

Bio-Path Holdings Announces $4.0 Million Private Placement: Fueling the Future of Cancer Therapies,

Published Wed, Oct 9 2024 12:00 AM UTC

Bio-Path Holdingsn Strategic Capital Raise: A Catalyst for Cancer InnovationIn a notable development for Bio-Path Holdings, Inc. (NASDAQ: BPTH), the biotechnology company announced on October 8, 2024, its entry into definitive agreements for the issuance and sale of approximately 4.6 million shares of common stock as part of a private placement deal estimated at $4 million....
Clinical Study

Promising Advances in Advanced Solid Tumor Treatment BP1001-A Shows Early Efficacy in Phase 1/1b Clinical Trial

Published Wed, Aug 21 2024 11:00 AM UTC

In a promising development for oncology, Bio-Path Holdings, Inc. has reported vital findings from its ongoing Phase 1/1b clinical trial of BP1001-A, a significant candidate for the treatment of advanced solid tumors. With the first patient receiving a second, higher dose of the trial drug, initial outcomes have revealed a noteworthy tumor reduction and stable disease status,...
Clinical Study

Bio-Path Holdings Unveiling Promising Clinical Progress and Ambitious Expansion Strategies in Overcoming Oncological ...

Published Mon, Jul 8 2024 11:00 AM UTC

CSIMarket.com presents an overview of recent updates from Bio-Path Holdings, focusing on their clinical progress and expansion plans in the treatment of various cancer indications. The article highlights the positive results from ongoing phase 2 combination studies of Prexigebersen, specifically for the treatment of Acute Myeloid Leukemia (AML) in high-risk patients. These...
Clinical Study

Unleashing Hope Acute Myeloid Leukemia Market Set to Soar as Clinical Trials Pave the Way

Published Mon, Jun 17 2024 1:45 PM UTC

Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials IncreasePALM BEACH, Fla., June 17, 2024 - According to a report from Mordor Intelligence, the Acute Myeloid Leukemia (AML) market is projected to reach a size of USD 2.97 billion by 2029, growing at a CAGR of 10.15% during the forecast period (2024-2029). This market is estimated to...
Clinical Study

Prexigebersen Combination Shows Promising Results in High-Risk Patients with Acute Myeloid Leukemia

Published Fri, Jun 14 2024 11:00 AM UTC

Bio-Path Holdings recently presented encouraging data from an ongoing phase 2 combination study of Prexigebersen at the European Hematology Association (EHA) Congress. The presentation highlighted positive outcomes from an interim analysis, revealing significant clinical improvement and a tolerable safety profile when using Prexigebersen in combination with other therapies f...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com